Evidence map›Paper›PMID 41246380›Full record

ArticleASM case reports2025

Anti-NMDA receptor encephalitis following Murray Valley encephalitis: a case report.

Arvind Yerramilli, Prashanth Ramachandran, John Burston, Annaleise R Howard-Jones, Chuan Kok Lim, Jen Kok, Leigh Fitzpatrick, Peter Hingston, Justin Jackson

Abstract readCase Reports
In one paragraph

Article in ASM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Arvind YerramilliDepartment of Medicine, Albury-Wodonga Health, Albury, New South Wales, Australia.
Prashanth RamachandranDepartment of Infectious Diseases at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
John BurstonDepartment of Medicine, Albury-Wodonga Health, Albury, New South Wales, Australia.
Annaleise R Howard-JonesDepartment of Infectious Diseases and Microbiology, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
Chuan Kok LimDepartment of Infectious Diseases at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-2828-2922
Jen KokCenter for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology-Institute of Clinical Pathology and Medical Research, Center for Infectious Diseases-Public Health, Westmead Hospital, Westmead, New South Wales, Australia.
Leigh FitzpatrickDepartment of Medicine, Albury-Wodonga Health, Albury, New South Wales, Australia.
Peter HingstonDepartment of Neurology, St. Vincent's Hospital, Fitzroy, Victoria, Australia.
Justin JacksonDepartment of Medicine, Albury-Wodonga Health, Albury, New South Wales, Australia.ORCID https://orcid.org/0000-0003-4151-9194

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an autoimmune condition that is increasingly being recognized as a complication of central nervous system infections. While association with herpes simplex virus encephalitis is well established, the condition has also been reported to occur following Japanese encephalitis virus infection and yellow fever vaccination. Case Summary: Here, we report a case of anti-NMDA receptor encephalitis following infection with Murray Valley encephalitis virus (MVEV), another virus of the family Flaviviridae. Following initial recovery, and 34 days after the onset of illness, our patient developed autonomic instability, orofacial dyskinesia, and decreased level of consciousness. Diagnosis was established with the detection of anti-NMDA receptor antibodies in cerebrospinal fluid. Immunosuppressive therapy with rituximab and corticosteroids resulted in a favorable outcome. Conclusion: This case report raises awareness of post-viral autoimmune encephalitis which should be considered in patients with a biphasic pattern of illness following viral encephalitis or a compatible clinical syndrome. Given the initial diagnosis of Murray Valley encephalitis, clinicians should be alert to the possibility of MVEV as an infectious trigger associated with the development of anti-NMDA receptor encephalitis. We also highlight the challenges inherent in the diagnosis of flavivirus infections, which may require a combination of clinical, epidemiological, and laboratory evidence.

Indexed as

anti-NMDA receptor encephalitisAustraliaautoimmune encephalitisflavivirusMurray Valley encephalitispost-viral encephalitis

Identifiers

PMID41246380
PMCPMC12530218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.